NCT02201459 2025-10-02
PETALs
Hospices Civils de Lyon
Phase 3 Completed
Clinical Trials
10 trialsNCT00452023 2024-12-11
Pegasys® in Patients With Myeloproliferative Diseases
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01387763 2022-04-27
DALIAH
Odense University Hospital
Phase 3 Completed
NCT02407080 2019-09-12
Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT01259856 2019-04-30
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Icahn School of Medicine at Mount Sinai
Phase 3 Completed
NCT01259817 2017-01-11
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT02829775 2017-01-09
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
Hoffmann-La Roche
Phase 2/3 Completed
NCT02736721 2016-09-20
Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)
Hoffmann-La Roche
Phase 3 Completed
NCT00241241 2015-10-21
Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera
PV-Nord
Phase 2 Completed
NCT00763763 2011-10-05
AFR07
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed